On March 17, 2022, Biological Dynamics, Inc. announced the publication of its study, “Early-Stage Multi-Cancer Detection Using an Extracellular Vesicle Protein-Based Blood Test,” published online on March 17, 2022 in an open-access article in Nature Communications Medicine. The blood test correctly identified 71 percent of stage 1 cancers in a combined cohort of pancreatic, ovarian, and bladder cancers, with pancreatic stage 1 cancer detection at 96%. “The results are remarkable and highlight exosomal protein markers as a viable candidate for early-stage cancer detection,” said Scott Lippman, MD, co-senior author of this report and Director of the UC San Diego Moores Cancer Center. “Specifically, pancreatic cancer is notoriously difficult to detect at an early stage, when surgery, the only curative therapy, is possible. Biological Dynamics’ assay is demonstrating the potential for early-stage cancer detection to be included in the standard of care."
Biological Dynamics Study Demonstrates Detection of Early-Stage Cancers Using Isolated Exosomes and AI-Enabled Protein Marker Analysis; “Results Are Remarkable” Researcher Says; 96% of Stage 1 Pancreatic Cancers Detected by Company’s Proprietary Platform
Login Or Register To Read Full Story